Why Rocket Lab Stock Shot 30% Higher This Week

Rocket Lab shares surged about 30% to $63.44 on Dec. 12, 2025 after reports that SpaceX may pursue a $1.5 trillion IPO in 2026 (potentially raising ~$30 billion) and after Rocket Lab advanced testing of its larger Neutron rocket’s “Hungry Hippo” fairing; sector excitement around a high‑profile SpaceX listing is boosting sentiment for public launch providers. The company posted 48% year‑over‑year revenue growth to $155 million last quarter and its stock is up more than 10x since early 2024, but at a $34 billion market cap and a price‑to‑sales ratio north of 50 the shares look extremely stretched, leaving fundamental upside contingent on successful Neutron flights and realization of the SpaceX IPO catalyst.

Analysis

Shares of Rocket Lab jumped roughly 30% to $63.44 on December 12, 2025 following reports that SpaceX may pursue a $1.5 trillion IPO in 2026 (potentially raising ~$30 billion) and after Rocket Lab advanced testing of the Neutron rocket’s "Hungry Hippo" fairing; the market reaction reflects sector-wide sentiment spillover rather than new firm-level contracts. Rocket Lab reported revenue of $155 million last quarter, up 48% year‑over‑year, and the stock has rallied more than 10x since early 2024 when shares traded below $5, indicating strong recent growth momentum. At a $34 billion market capitalization and a price‑to‑sales ratio north of 50, the equity appears highly stretched relative to current revenue, leaving valuation exposed to near‑term execution risk. The company’s outlook is now binary: material upside depends on successful Neutron full flights and commercialization in 2026 and on whether a SpaceX IPO sustains sector demand; conversely, delays or a cooling of IPO enthusiasm would likely reverse recent gains given speculative sentiment (sentiment labeled mixed, market impact moderate).

Key Decisions for Investors

• Avoid initiating large, unhedged long positions in RKLB at current levels given a market cap of $34 billion and P/S above 50 which provide limited fundamental margin of safety
• If currently long, consider trimming positions and implementing downside protection (protective puts or collars) ahead of Neutron full‑flight tests and any SpaceX IPO developments
• Treat further allocation as conditional and staged: increase exposure only after confirmed successful Neutron flights, clear commercial launch contracts, or sustained quarterly revenue/margin improvement
• Monitor three near‑term indicators closely—Neutron test outcomes and commercial launch timetable, Rocket Lab contract/backlog disclosures, and verifiable progress or timing on a SpaceX IPO—and reassess positioning if any of these signals deteriorate